AMNEAL PHARMACEUTICALS INC (AMRX)

US03168L1052 - Common Stock

5.87  -0.03 (-0.51%)

After market: 5.74 -0.13 (-2.21%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
2.094B
5.08%		2.212B
5.67%		2.394B
8.20%		2.66B
11.13%
EBITDA
YoY % growth
449.804M
18.03%		439.477M
-2.30%		504.247M
14.74%		613.22M
21.61%
EBIT
YoY % growth
216.398M
48.52%		199.302M
-7.90%		274.847M
37.90%		537.77M
95.66%
Operating Margin
10.34%9.01%11.48%20.22%
EPS
YoY % growth
0.84
33.33%		0.68
-19.05%		N/A0.59

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		0.11
-5.44%
Revenue
Q2Q % growth		612.27M
9.82%
EBITDA
Q2Q % growth		132.45M
EBIT
Q2Q % growth		110.82M
221.00%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 0.14
-39.13%		0.090.0552.17%
Q3 2023
Q2Q % growth		 0.19
35.71%		0.130.0646.90%
Q2 2023
Q2Q % growth		 0.19 0.110.0875.73%
Q1 2023
Q2Q % growth		 0.12 0.100.0222.55%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 616.981M
1.18%		646.91M-29.929M-4.63%
Q3 2023
Q2Q % growth		 620.04M
13.65%		607.18M12.86M2.12%
Q2 2023
Q2Q % growth		 599.046M
7.10%		576.72M22.326M3.87%
Q1 2023
Q2Q % growth		 557.54M
12.04%		548.05M9.49M1.73%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% 0.34%
Revenue0% 0% 0.83% 1.88%